Nautilus Biotechnology, INC 8-K filings

Nautilus Biotechnology, Inc. held its 2026 annual meeting, where stockholders elected Class II directors, ratified the appointment of PricewaterhouseCoopers LLP, and approved executive compensation and the frequency of future advisory votes.

Nautilus Biotechnology reported reduced operating expenses and net loss for Q4 and FY 2025, while launching its Iterative Mapping Early Access Program.

Nautilus Biotechnology, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Nautilus Biotechnology reported a reduced net loss and decreased operating expenses in Q3 2025, while making progress towards its late 2026 commercial launch.

Nautilus Biotechnology reports reduced Q2 2025 net loss and operating expenses, alongside significant scientific milestones and new research collaborations.

Nautilus Biotechnology, Inc. announced the results of its 2025 annual meeting of stockholders, including the election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Nautilus Biotechnology received a notification from Nasdaq on May 1, 2025, indicating that it does not meet the minimum bid price requirement of $1.00 per share for continued listing.

Nautilus Biotechnology announced its Q1 2025 financial results, showcasing progress in its Tau proteoform assay development and a decrease in operating expenses.

Nautilus Biotechnology announced its Q4 and fiscal year 2024 financial results, highlighting flat operating expenses for the quarter and a revised timeline for its proteome analysis platform launch.

Nautilus Biotechnology reports that directors Vijay Pande and Michael Altman will not seek re-election at the 2025 annual meeting.

Nautilus Biotechnology announced its third quarter 2024 financial results, highlighting flat operating expenses compared to the same period last year and a net loss of $16.4 million.

Nautilus Biotechnology announced its second quarter 2024 financial results, highlighting continued progress in the development of its single-molecule proteome analysis platform.

Nautilus Biotechnology held its 2024 annual meeting, electing three Class III directors and ratifying PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2024.

Nautilus Biotechnology reported a 20% increase in operating expenses and a larger net loss for the first quarter of 2024 compared to the same period last year, driven by increased headcount to support product development.

Nautilus Biotechnology has entered into a sales agreement with TD Cowen to sell up to $125 million of its common stock through an at-the-market offering program.

Nautilus Biotechnology announced its financial results for the fourth quarter and fiscal year 2023, highlighting progress in platform development and providing a financial outlook for 2024.